Haleon plc (HLNCF)
| Previous Close | 3.6000 |
| Open | 3.6000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 3.6000 - 3.6000 |
| 52 Week Range | 0.0001 - 4.0400 |
| Volume | |
| Avg. Volume | 4,775 |
| Market Cap | 37.399B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 18.95 |
| EPS (TTM) | 0.1900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Bloomberg
Advil Maker Haleon Said to Study Potential Deals to Bulk Up
(Bloomberg) -- Haleon Plc, the consumer health business spun out from British pharmaceutical producer GSK Plc, is in the early stages of studying large potential deals to bulk up its brand portfolio, people with knowledge of the matter said. Most Read from BloombergSony Slashes PlayStation VR2 Headset Output After Pre-Orders DisappointPutin’s War in Ukraine Pushes Ex-Soviet States Toward New AlliesBrexit Is Costing the UK £100 Billion a Year in Lost OutputTrump Sues Journalist Bob Woodward for R
- Zacks
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
- Simply Wall St.
Haleon plc (LON:HLN) Delivered A Weaker ROE Than Its Industry
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
